TMCnet News

Sutent 2016-2017 U.S Promotional Report - Research and Markets
[December 12, 2017]

Sutent 2016-2017 U.S Promotional Report - Research and Markets


The "Sutent 2016 U.S Promotional Report" report has been added to Research and Markets' offering.

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Sutent through personal promotion in 2016 and how does this compare to its peer set in the Gastrointestinal Stromal Tumors, Pancreatic Cancer, and Renal Cancer markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
  • How does Pfizer's depth of coverage vary within key specialties (e.g., Hematology/Oncology, Medical Oncology, and Internal Medicine) and how does this compare to its peers and the ovrall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Sutent throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most detailed prescribers and top paid speakers for Sutent in 2016?



Data Sources and Methodology:

  • We leverage company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 42 months of longitudinal data is available - covering payments to more than 900,000 U.S. healthcare professionals.
  • Over 7,100 paid interactions across 2,600 physicians made on behalf of Sutent were carefully examined to support our analysis. In addition, interaction data from 12 peer products (e.g. Abraxane, Afinitor, Avastin, Cabometyx, Inlyta, Nexavar, Onivyde, Opdivo, Stivarga, Tarceva, Torisel, and Votrient ) was leveraged to provide benchmarking and market insights.

For more information about this report visit https://www.researchandmarkets.com/research/j4vhqv/sutent_20162017?w=4



[ Back To TMCnet.com's Homepage ]